FIBROGEN INC
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
KYNB$3.73+1.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share amounts)
| December 31, 2023 | December 31, 2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $113,688 | $155,700 |
| Short-term investments | 121,898 | 266,308 |
| Accounts receivable, net ($6,079 and $12,088 from related parties) | 12,553 | 16,299 |
| Inventories | 41,565 | 40,436 |
| Prepaid expenses and other current assets | 41,855 | 14,083 |
| Total current assets | 331,559 | 492,826 |
| Restricted time deposits | 1,658 | 2,072 |
| Long-term investments | — | 4,348 |
| Property and equipment, net | 13,126 | 20,605 |
| Equity method investment in unconsolidated variable interest entity | 5,290 | 5,061 |
| Operating lease right-of-use assets | 68,093 | 79,893 |
| Other assets | 3,803 | 5,282 |
| Total assets | $423,529 | $610,087 |
| Liabilities, redeemable non-controlling interests and deficit | ||
| Current liabilities: | ||
| Accounts payable | $17,960 | $30,758 |
| Accrued and other current liabilities ($39,814 and $63,886 to a related party) | 172,891 | 219,773 |
| Deferred revenue ($7,220 and $9,259 to related parties) | 12,740 | 12,739 |
| Operating lease liabilities, current | 14,077 | 10,292 |
| Total current liabilities | 217,668 | 273,562 |
| Product development obligations | 17,763 | 16,917 |
| Deferred revenue, net of current ($9,705 and $31,044 to a related party) | 157,555 | 185,722 |
| Operating lease liabilities, non-current | 66,537 | 79,593 |
| Senior secured term loan facilities, non-current | 71,934 | — |
| Liability related to sale of future revenues, non-current | 51,413 | 49,333 |
| Other long-term liabilities ($656 and $0 to a related party) | 2,858 | 6,440 |
| Total liabilities | 585,728 | 611,567 |
| Commitments and Contingencies (Note 12) | ||
| Redeemable non-controlling interests | 21,480 | — |
| Stockholders’ deficit: | ||
| Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2023 and 2022; 98,770 and 94,166 shares issued and outstanding at December 31, 2023 and 2022 | 988 | 942 |
| Additional paid-in capital | 1,643,641 | 1,541,019 |
| Accumulated other comprehensive loss | (6,875) | (5,720) |
| Accumulated deficit | (1,841,920) | (1,557,688) |
| Total stockholders’ deficit attributable to FibroGen | (204,166) | (21,447) |
| Nonredeemable non-controlling interests | 20,487 | 19,967 |
| Total deficit | (183,679) | (1,480) |
| Total liabilities, redeemable non-controlling interests and deficit | $423,529 | $610,087 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.